Payment overview · 2025
General Payments
$494.63
25 reported records · 14 companies
Healthcare provider profile · identity verified
Alexander Hray, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BEAUFORT, SC · NPI 1083909121
Verified facts
What the public records show
CMS Open Payments records show Alexander Hray, M.D. received $494.63 in general payments during 2025 across 25 reported records.
PFIZER INC. accounted for 21.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $107.55 | 21.7% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $56.09 | 11.3% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $48.12 | 9.7% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $38.37 | 7.8% | 2 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $30.83 | 6.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $28.75 | 5.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $28.50 | 5.8% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $28.19 | 5.7% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $27.54 | 5.6% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $27.14 | 5.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $20.38 | 4.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.17 | 4.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.56 | 3.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.44 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $494.63 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $76.86 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $48.12 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $40.35 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $38.37 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $36.51 | 2 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $30.83 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $30.83 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $30.69 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $30.69 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $30.69 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $29.45 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $28.75 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $28.50 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $28.50 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $27.54 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $27.14 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $26.64 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $26.64 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $20.38 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.17 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.56 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 136 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 42 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 68 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 61 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 72 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
42 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
68 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
72 | 24 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
61 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
136 | 38 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 637 | 197 |
| Amlodipine Besylate | Amlodipine Besylate | 512 | 171 |
| Omeprazole | Omeprazole | 334 | 105 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 319 | 97 |
| Levothyroxine Sodium | Levothyroxine Sodium | 302 | 84 |
| Lisinopril | Lisinopril | 294 | 95 |
| Gabapentin | Gabapentin | 260 | 98 |
| Metformin Hcl | Metformin Hcl | 254 | 83 |
| Losartan Potassium | Losartan Potassium | 217 | 72 |
| Furosemide | Furosemide | 212 | 90 |
| Pantoprazole Sodium | Pantoprazole Sodium | 206 | 80 |
| Pravastatin Sodium | Pravastatin Sodium | 206 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 164 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 155 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 151 | 49 |
| Carvedilol | Carvedilol | 149 | 55 |
| Fluticasone Propionate | Fluticasone Propionate | 144 | 71 |
| Spironolactone | Spironolactone | 140 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 139 | 51 |
| Eliquis | Apixaban | 136 | 38 |
| Potassium Chloride | Potassium Chloride | 127 | 45 |
| Meloxicam | Meloxicam | 120 | 45 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 115 | 29 |
| Montelukast Sodium | Montelukast Sodium | 115 | 43 |
| Pioglitazone Hcl | Pioglitazone Hcl | 111 | 31 |
| Metformin Hcl Er | Metformin Hcl | 109 | 31 |
| Tramadol Hcl | Tramadol Hcl | 105 | 33 |
| Allopurinol | Allopurinol | 101 | 33 |
| Celecoxib | Celecoxib | 99 | 37 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 97 | 29 |
| Trazodone Hcl | Trazodone Hcl | 97 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 96 | 29 |
| Amitriptyline Hcl | Amitriptyline Hcl | 94 | 28 |
| Sertraline Hcl | Sertraline Hcl | 93 | 30 |
| Alendronate Sodium | Alendronate Sodium | 90 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 82 | 22 |
| Glimepiride | Glimepiride | 81 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 35 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 78 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 77 | 34 |
| Warfarin Sodium | Warfarin Sodium | 73 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 72 | 24 |
| Jardiance | Empagliflozin | 68 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 63 | 19 |
| Famotidine | Famotidine | 62 | 26 |
| Ozempic | Semaglutide | 61 | 20 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 58 | 13 |
| Januvia | Sitagliptin Phosphate | 58 | 14 |
| Prednisone | Prednisone | 56 | 44 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 56 | 31 |
| Glipizide | Glipizide | 55 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 53 | 16 |
| Ezetimibe | Ezetimibe | 53 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 18 |
| Simvastatin | Simvastatin | 51 | 16 |
| Valsartan | Valsartan | 51 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 44 | 13 |
| Chlorthalidone | Chlorthalidone | 44 | 14 |
| Bumetanide | Bumetanide | 43 | 16 |
| Pregabalin | Pregabalin | 43 | 16 |
| Donepezil Hcl | Donepezil Hcl | 42 | 16 |
| Farxiga | Dapagliflozin Propanediol | 42 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | 18 |
| Sumatriptan Succinate | Sumatriptan Succinate | 40 | suppressed |
| Atenolol | Atenolol | 36 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 13 |
| Cefdinir | Cefdinir | 33 | 32 |
| Lorazepam | Lorazepam | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 32 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | 13 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 32 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 13 |
| Sildenafil Citrate | Sildenafil Citrate | 31 | 13 |
| Glipizide Er | Glipizide | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Methocarbamol | Methocarbamol | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Temazepam | Temazepam | 28 | suppressed |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 23 |
| Tresiba Flextouch U-200 | Insulin Degludec | 26 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 24 | 24 |
| Meclizine Hcl | Meclizine Hcl | 24 | 11 |
| Naproxen | Naproxen | 24 | 17 |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 16 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Klor-Con M20 | Potassium Chloride | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | 11 |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | 11 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 17 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 12 |
| Klor-Con M10 | Potassium Chloride | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Alprazolam | Alprazolam | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Indapamide | Indapamide | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 14 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | 11 |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $494.63 · 25 records | PFIZER INC. | ABRYSVO, AREXVY, COMIRNATY, CT THROMBECTOMY SYSTEM KIT, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FLOWTRIEVER CATHETER, S, FREESTYLE LIBRE 3, GEMTESA, INSPIRE, JARDIANCE, LEQVIO, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Veozah, ZAVZPRET | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error